TY - JOUR
T1 - Human beta-defensin 1, a new animal toxin-like blocker of potassium channel
AU - Feng, Jing
AU - Xie, Zili
AU - Yang, Weishan
AU - Zhao, Yonghui
AU - Xiang, Fang
AU - Cao, Zhijian
AU - Li, Wenxin
AU - Chen, Zongyun
AU - Wu, Yingliang
N1 - Funding Information:
This work was supported by grants from the National Natural Sciences Foundation of China (Nos. 31470812 and 31170789 ), National Science Fund for Excellent Young Scholars (No. 31422049 ), and Wuhan University Natural Sciences Foundation (No. 2042015kf0168 ). The authors declare no competing financial interests.
Publisher Copyright:
© 2016 Elsevier Ltd. All rights reserved.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - The discovery of human β-defensin 2 (hBD2), as a Kv1.3 channel inhibitor with the unique molecular mechanism and novel immune modulatory function, suggests that human β-defensins are a novel class of channel ligands. Here, the function and mechanism of the human β-defensin 1 (hBD1) binding to potassium channels was investigated. Based on the structural similarity between hBD1 and Kv1.3 channel-sensitive hBD2, hBD1 was found to selectively inhibit human and mouse Kv1.3 channels with IC50 values of 11.8 ± 3.1 μM and 13.2 ± 4.0 μM, respectively. Different from hBD2 modifying Kv1.3 channel activation and increasing activation time constant, hBD1 did not affect the activation feature of both human and mouse Kv1.3 channels. In comparison with hBD2 simultaneously interacting with the extracellular S1-S2 linker and pore region of Kv1.3 channel, the chimeric channel and mutagenesis experiments showed that hBD1 only bound to the extracellular pore region of Kv1.3 channel instead of extracellular S1-S2 linker or S3-S4 linker. Together, these findings enhance knowledge of hBD1 as a new immune-related Kv1.3 channel blocker and highlight the major functional differences between hBD1 and hBD2 to explore in future research.
AB - The discovery of human β-defensin 2 (hBD2), as a Kv1.3 channel inhibitor with the unique molecular mechanism and novel immune modulatory function, suggests that human β-defensins are a novel class of channel ligands. Here, the function and mechanism of the human β-defensin 1 (hBD1) binding to potassium channels was investigated. Based on the structural similarity between hBD1 and Kv1.3 channel-sensitive hBD2, hBD1 was found to selectively inhibit human and mouse Kv1.3 channels with IC50 values of 11.8 ± 3.1 μM and 13.2 ± 4.0 μM, respectively. Different from hBD2 modifying Kv1.3 channel activation and increasing activation time constant, hBD1 did not affect the activation feature of both human and mouse Kv1.3 channels. In comparison with hBD2 simultaneously interacting with the extracellular S1-S2 linker and pore region of Kv1.3 channel, the chimeric channel and mutagenesis experiments showed that hBD1 only bound to the extracellular pore region of Kv1.3 channel instead of extracellular S1-S2 linker or S3-S4 linker. Together, these findings enhance knowledge of hBD1 as a new immune-related Kv1.3 channel blocker and highlight the major functional differences between hBD1 and hBD2 to explore in future research.
KW - Endogenous blocker
KW - Function and mechanism
KW - Human β-defensin 1
KW - Human β-defensin 2
KW - Kv1.3 channel
UR - http://www.scopus.com/inward/record.url?scp=84957588496&partnerID=8YFLogxK
U2 - 10.1016/j.toxicon.2016.02.007
DO - 10.1016/j.toxicon.2016.02.007
M3 - Article
C2 - 26854370
AN - SCOPUS:84957588496
VL - 113
SP - 1
EP - 6
JO - Toxicon
JF - Toxicon
SN - 0041-0101
ER -